Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Stent-oriented versus patient-oriented outcome in patients undergoing early percutaneous coronary intervention for acute coronary syndrome: 2-year report from the BASE-ACS trial.

Romppanen H, Nammas W, Kervinen K, Airaksinen JK, Pietilä M, Rivero-Crespo F, Debelder A, Tedjokusumo P, Mikkelsson J, Ylitalo A, Karjalainen PP.

Ann Med. 2013 Nov;45(7):488-93. doi: 10.3109/07853890.2013.833390. Epub 2013 Sep 13.

PMID:
24032547
[PubMed - indexed for MEDLINE]
2.

Outcome of ST-elevation myocardial infarction versus non-ST-elevation acute coronary syndrome treated with titanium-nitride-oxide-coated versus everolimus-eluting stents: insights from the BASE-ACS trial.

Romppanen H, Nammas W, Kervinen K, Mikkelsson J, Pietilä M, Lalmand J, Rivero-Crespo F, Pentikäinen M, Tedjokusumo P, Karjalainen PP.

Minerva Cardioangiol. 2013 Apr;61(2):201-9.

PMID:
23492603
[PubMed - indexed for MEDLINE]
3.

Neointimal coverage and vasodilator response to titanium-nitride-oxide-coated bioactive stents and everolimus-eluting stents in patients with acute coronary syndrome: insights from the BASE-ACS trial.

Karjalainen P, Kiviniemi TO, Lehtinen T, Nammas W, Ylitalo A, Saraste A, Mikkelsson J, Pietila M, Biancari F, Airaksinen JK.

Int J Cardiovasc Imaging. 2013 Dec;29(8):1693-703. doi: 10.1007/s10554-013-0285-8. Epub 2013 Aug 31. Erratum in: Int J Cardiovasc Imaging. 2013 Dec;29(8):1915. Kiviniemi, Tuomas O [added]; Lehtinen, Tuomas [added]; Nammas, Wail [added]; Ylitalo, Antti [added]; Saraste, Antti [added]; Mikkelsson, Jussi [added]; Pietila, Mikko [added]; Biancari, Fausto [added]; Airaksinen, Juhani K E [added].

PMID:
23996244
[PubMed - indexed for MEDLINE]
4.

A prospective randomised comparison of titanium-nitride-oxide-coated bioactive stents with everolimus-eluting stents in acute coronary syndrome: the BASE-ACS trial.

Karjalainen PP, Niemelä M, Airaksinen JK, Rivero-Crespo F, Romppanen H, Sia J, Lalmand J, de Bruyne B, Debelder A, Carlier M, Nammas W, Ylitalo A, Hess OM; BACE-ACS study investigators.

EuroIntervention. 2012 Jul 20;8(3):306-15. doi: 10.4244/EIJV8I3A49.

PMID:
22829506
[PubMed - indexed for MEDLINE]
Free Article
5.

Five-year clinical outcome of titanium-nitride-oxide-coated bioactive stents versus paclitaxel-eluting stents in patients with acute myocardial infarction: long-term follow-up from the TITAX AMI trial.

Tuomainen PO, Ylitalo A, Niemelä M, Kervinen K, Pietilä M, Sia J, Nyman K, Nammas W, Airaksinen KE, Karjalainen PP.

Int J Cardiol. 2013 Sep 30;168(2):1214-9. doi: 10.1016/j.ijcard.2012.11.060. Epub 2012 Dec 3.

PMID:
23218575
[PubMed - indexed for MEDLINE]
6.

Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial.

Sabate M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Gómez-Hospital JA, Baz JA, Martin-Yuste V, van Geuns RJ, Alfonso F, Bordes P, Tebaldi M, Masotti M, Silvestro A, Backx B, Brugaletta S, van Es GA, Serruys PW.

Lancet. 2012 Oct 27;380(9852):1482-90. doi: 10.1016/S0140-6736(12)61223-9. Epub 2012 Sep 3.

PMID:
22951305
[PubMed - indexed for MEDLINE]
8.

Gender-based analysis of randomized comparison of bioactive versus everolimus-eluting stents in acute coronary syndrome.

Sia J, Nammas W, Niemelä M, Airaksinen JK, Lalmand J, Laine M, Tedjokusumo P, Nyman K, Biancari F, Karjalainen PP.

J Cardiovasc Med (Hagerstown). 2014 Jul 4. [Epub ahead of print]

PMID:
25003998
[PubMed - as supplied by publisher]
9.

Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.

von Birgelen C, Sen H, Lam MK, Danse PW, Jessurun GA, Hautvast RW, van Houwelingen GK, Schramm AR, Gin RM, Louwerenburg JW, de Man FH, Stoel MG, Löwik MM, Linssen GC, Saïd SA, Nienhuis MB, Verhorst PM, Basalus MW, Doggen CJ, Tandjung K.

Lancet. 2014 Feb 1;383(9915):413-23. doi: 10.1016/S0140-6736(13)62037-1. Epub 2013 Oct 31. Erratum in: Lancet. 2014 Feb 1;383(9915):412.

PMID:
24183564
[PubMed - indexed for MEDLINE]
10.
11.

Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).

Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS Jr, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW.

JACC Cardiovasc Interv. 2013 Sep;6(9):914-22. doi: 10.1016/j.jcin.2013.05.005.

PMID:
24050859
[PubMed - indexed for MEDLINE]
12.

Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.

Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker-Havinga T, van Es GA, Meier B, Jüni P, Windecker S.

JACC Cardiovasc Interv. 2013 Aug;6(8):777-89. doi: 10.1016/j.jcin.2013.04.011.

PMID:
23968698
[PubMed - indexed for MEDLINE]
13.

Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.

Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL; SPIRIT III Investigators.

Circulation. 2009 Feb 10;119(5):680-6. doi: 10.1161/CIRCULATIONAHA.108.803528. Epub 2009 Jan 26.

PMID:
19171853
[PubMed - indexed for MEDLINE]
Free Article
14.

Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.

Wiemer M, Serruys PW, Miquel-Hebert K, Neumann FJ, Piek JJ, Grube E, Haase J, Thuesen L, Hamm C.

Catheter Cardiovasc Interv. 2010 Jun 1;75(7):997-1003. doi: 10.1002/ccd.22428.

PMID:
20517959
[PubMed - indexed for MEDLINE]
15.

Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial.

Brener SJ, Kereiakes DJ, Simonton CA, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Smith RS Jr, Ying SW, Cutlip DE, Stone GW.

Am Heart J. 2013 Dec;166(6):1035-42. doi: 10.1016/j.ahj.2013.08.030. Epub 2013 Oct 31.

PMID:
24268218
[PubMed - indexed for MEDLINE]
16.

2-year patient-related versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) Trial.

Jensen LO, Thayssen P, Christiansen EH, Tilsted HH, Maeng M, Hansen KN, Kaltoft A, Hansen HS, Bøtker HE, Krusell LR, Ravkilde J, Madsen M, Thuesen L, Lassen JF; SORT OUT IV Investigators.

J Am Coll Cardiol. 2012 Sep 25;60(13):1140-7. doi: 10.1016/j.jacc.2012.07.004. Epub 2012 Sep 5.

PMID:
22958957
[PubMed - indexed for MEDLINE]
Free Article
17.

Comparison of twelve-month outcomes after percutanous coronary intervention with everolimus-eluting versus zotarolimus-eluting or sirolimus-eluting stents from the PROENCY (PROmus ENdeavor CYpher) registry.

Damman P, Abdel-Wahab M, Möllmann H, Richardt G, Chevalier B, Barragan P, Tijssen JG, Underwood P, Hamm CW.

J Invasive Cardiol. 2012 Oct;24(10):495-502.

PMID:
23043032
[PubMed - indexed for MEDLINE]
Free Article
18.

Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.

Tandjung K, Sen H, Lam MK, Basalus MW, Louwerenburg JH, Stoel MG, van Houwelingen KG, de Man FH, Linssen GC, Saïd SA, Nienhuis MB, Löwik MM, Verhorst PM, van der Palen J, von Birgelen C.

J Am Coll Cardiol. 2013 Jun 18;61(24):2406-16. doi: 10.1016/j.jacc.2013.04.005. Epub 2013 Apr 16.

PMID:
23602769
[PubMed - indexed for MEDLINE]
Free Article
19.

Gender-based analysis of the 3-year outcome of bioactive stents versus paclitaxel-eluting stents in patients with acute myocardial infarction: an insight from the TITAX-AMI trial.

Tuomainen PO, Ylitalo A, Niemelä M, Kervinen K, Pietilä M, Sia J, Nyman K, Nammas W, Airaksinen KE, Karjalainen PP.

J Invasive Cardiol. 2012 Mar;24(3):104-8.

PMID:
22388300
[PubMed - indexed for MEDLINE]
Free Article
20.

Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.

Harjai KJ, Kondareddy S, Pinkosky B, Harjai N, Orshaw P, Boura J.

J Interv Cardiol. 2013 Apr;26(2):153-62. doi: 10.1111/j.1540-8183.2013.12016.x. Epub 2013 Jan 31.

PMID:
23363439
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk